Patents by Inventor Il Chan Kim

Il Chan Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11911749
    Abstract: Provided are a chromium catalyst precursor, an ethylene oligomerization catalyst including the same, and a method of preparing an ethylene oligomer using the same. More particularly, a chromium catalyst precursor which may oligomerize ethylene with high activity and high selectivity in spite of not using methylaluminoxane (MAO) or modified-methylaluminoxane (MMAO), an oligomerization catalyst including the same, and a method of preparing an ethylene oligomer using the same are provided.
    Type: Grant
    Filed: August 18, 2022
    Date of Patent: February 27, 2024
    Assignee: SK Innovation Co., Ltd.
    Inventors: Il Gu Jung, Hyo Seung Park, Jun Soo Son, Myung Jin Kim, Jong Chan Kim
  • Publication number: 20220281805
    Abstract: A lobamide compound according to an embodiment of the present disclosure is represented by Formula 1. The lobamide compound has excellent PTP-1B inhibitory activity that is far higher than that of conventional lobaric acid derivatives and which can be orally administered, and thus is very effective in the prevention or treatment of diabetes or obesity through oral administration.
    Type: Application
    Filed: August 14, 2020
    Publication date: September 8, 2022
    Inventors: Joung Han YIM, Il Chan KIM, Se Jong HAN, Tai Kyoung KIM, Dong Gyu JO, Hyun Cheol OH, Ha Ju PARK, Seul Ki MIN, Sung Jin KIM, Pil Sung KANG, Min Ju KIM, Jung Eun KIM, Kyung Hee KIM, Ju Mi HONG
  • Patent number: 11434217
    Abstract: The present invention can synthesize lobaric acid and four analogues thereof, which are five phenolic lichen metabolites isolated from an extract of the Antarctic lichen Stereocaulon alpinum and selectively inhibit PTP1B, by a simple, economic and efficient chemical synthesis method.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: September 6, 2022
    Assignee: KOREA INSTITUTE OF OCEAN SCIENCE AND TECHNOLOGY
    Inventors: Joung Han Yim, Il-Chan Kim, Se Jong Han, Ui Joung Youn, Hong Kum Lee, Jun Hyuck Lee, Tai Kyoung Kim, Kwon Joo Yeo
  • Publication number: 20210177796
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory diseases and a food for preventing or alleviating inflammatory diseases, both of which contain curvularin-type metabolites as an active ingredient and, more specifically to a pharmaceutical composition for preventing or treating inflammatory diseases and a food for preventing or alleviating inflammatory diseases, both of which contain, as an active ingredient, marine fungus Penicillium sp. SF-5859-derived curvularin-type metabolites. A pharmaceutical composition, according to the present invention, for preventing or treating inflammatory diseases, containing curvularin-type metabolites derived from marine fungus Penicillium sp. SF-5859 (KCTC 13354 BP) inhibits the production of proinflammatory cytokines and mediators, thereby being effectively usable for the prevention or treatment of inflammatory diseases.
    Type: Application
    Filed: February 28, 2018
    Publication date: June 17, 2021
    Inventors: Joung Han YIM, Il-Chan KIM, Se Jong HAN, Ui Joung YOUN, Hyun Cheol OH, Youn-Chul KIM, Jae Hak SOHN, Minh Ha TRAN, Wonmin KO, Seung Jun LEE, Jae-Young SON
  • Patent number: 10993434
    Abstract: The present invention relates to an exopolysaccharide derived from Pseudoalteromonas sp. strain CY01 (KCTC 12867BP) which is a novel strain living in the polar regions, and to a composition for cryoprotection of cells, which contains the exopolysaccharide. The exopolysaccharide of the present invention has an excellent ability to cryoprotect cells, and shows no cytotoxicity. Thus, the inventive exopolysaccharide can substitute for conventional cryoprotective agents that show cytotoxicity when used at high concentrations.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: May 4, 2021
    Assignee: Korea Institute of Ocean Science and Technology
    Inventors: Joung Han Yim, Il-Chan Kim, Se Jong Han, Ui Joung Youn, Hong Kum Lee, Sung Jin Kim, Pil-Sung Kang, Jung Eun Kim, Tai Kyoung Kim, Ha Ju Park, Jin Haeng Song, Min Ju Kim, Ju Mi Hong, Dong-Gyu Jo
  • Publication number: 20180325101
    Abstract: The present invention relates to an exopolysaccharide derived from Pseudoalteromonas sp. strain CY01 (KCTC 12867BP) which is a novel strain living in the polar regions, and to a composition for cryoprotection of cells, which contains the exopolysaccharide. The exopolysaccharide of the present invention has an excellent ability to cryoprotect cells, and shows no cytotoxicity. Thus, the inventive exopolysaccharide can substitute for conventional cryoprotective agents that show cytotoxicity when used at high concentrations.
    Type: Application
    Filed: December 8, 2017
    Publication date: November 15, 2018
    Inventors: Joung Han Yim, Il-Chan Kim, Se Jong Han, Ui Joung Youn, Hong Kum Lee, Sung Jin Kim, Pil-Sung Kang, Jung Eun Kim, Tai Kyoung Kim, Ha Ju Park, Jin Haeng Song, Min Ju Kim, Ju Mi Hong, Dong-Gyu Jo
  • Patent number: 9968576
    Abstract: The present invention relates to a neurodegenerative disease treatment use, which is a novel use of Ramalin, and, more specifically, to a composition for preventing or treating neurodegenerative diseases, containing Ramalin, which has an inflammasome and BACE1 expression inhibitory activity. Ramalin according to the present invention has an effect of improving a cognitive ability by inhibiting the expression of an inflammatory factor, which contains an NLRP inflammasome protein, and BACE1, and is thus useful for preventing or treating memory disorder and neurodegenerative diseases.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: May 15, 2018
    Assignee: KOREA INSTITUTE OF OCEAN SCIENCE AND TECHNOLOGY
    Inventors: Joung Han Yim, Il-Chan Kim, Se Jong Han, Dong-Gyu Jo
  • Publication number: 20170304244
    Abstract: The present invention relates to a neurodegenerative disease treatment use, which is a novel use of Ramalin, and, more specifically, to a composition for preventing or treating neurodegenerative diseases, containing Ramalin, which has an inflammasome and BACE1 expression inhibitory activity. Ramalin according to the present invention has an effect of improving a cognitive ability by inhibiting the expression of an inflammatory factor, which contains an NLRP inflammasome protein, and BACE1, and is thus useful for preventing or treating memory disorder and neurodegenerative diseases.
    Type: Application
    Filed: October 24, 2014
    Publication date: October 26, 2017
    Inventors: Joung Han Yim, Il-Chan Kim, Se Jong Han, Dong-Gyu Jo
  • Patent number: 9644194
    Abstract: A cold-adapted protease derived from Pseudoalteromonas arctica PAMC 21717 or a recombinant cold-adapted protease obtained by expressing a gene encoding the cold-adapted protease in E. coli is described, and more particularly, a crystal of a protease exhibiting activity at low temperatures, a method for crystallizing the protease, a method for preparing the protease, a recombinant microorganism that expresses the protease, a method for preparing the recombinant microorganism, a method for preparing the recombinant protease and the use of the cold-adapted protease. The cold-adapted protease exhibits high activity at low temperatures, and securely maintains its enzymatic activity even in the presence of high pH, various metal ions and surfactants. Thus, it is useful in various industrial applications.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: May 9, 2017
    Assignee: KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY
    Inventors: Joung Han Yim, Bon-Hun Koo, Chul Soo Shin, Dockyu Kim, Il-Chan Kim, Se Jong Han, Jun Hyuck Lee, Ha Ju Park
  • Patent number: 9574185
    Abstract: A cold-adapted protease derived from Pseudoalteromonas arctica PAMC 21717 or a recombinant cold-adapted protease obtained by expressing a gene encoding the cold-adapted protease in E. coli is described, and more particularly, a crystal of a protease exhibiting activity at low temperatures, a method for crystallizing the protease, a method for preparing the protease, a recombinant microorganism that expresses the protease, a method for preparing the recombinant microorganism, a method for preparing the recombinant protease and the use of the cold-adapted protease. The cold-adapted protease exhibits high activity at low temperatures, and securely maintains its enzymatic activity even in the presence of high pH, various metal ions and surfactants. Thus, it is useful in various industrial applications.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: February 21, 2017
    Assignee: KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY
    Inventors: Joung Han Yim, Bon-Hun Koo, Chul Soo Shin, Dockyu Kim, Il-Chan Kim, Se Jong Han, Jun Hyuck Lee, Ha Ju Park
  • Patent number: 9539227
    Abstract: The present invention relates to the novel use (anti-inflammatory activity) of Ramalin isolated from the Antarctic lichen Ramalina terebrata, and more specifically to a pharmaceutical composition containing Ramalin as an active ingredient. Ramalin of the invention is a compound derived from natural material, has no toxicity or side effects, and inhibits the expression of inducible nitric oxide synthase (iNOS) in the transcription stage to significantly inhibit the production of nitric oxide (NO) that is a key mediator of inflammatory responses. In addition, it inhibits the activation of the inflammatory mediator NF-?B, inhibits p38 MAPK, ERK1/2 and JNK signaling pathways, and inhibits the expression of the LPS receptor TLR4, suggesting that Ramalin has an excellent anti-inflammatory effect. Thus, the composition containing Ramalin can be effectively used to fundamentally treat or prevent inflammatory diseases or immune diseases and to relieve or alleviate the symptoms of the diseases.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: January 10, 2017
    Assignee: KOREA OCEAN RESEARCH AND DEVELOPMENT INSTITUTE
    Inventors: Joung Han Yim, Il Chan Kim, Sung Gu Lee, Doc Kyu Kim, Se Jong Han, Hyoung Seok Lee, Sung Jin Kim, Tai Kyoung Kim, Pil-Sung Kang, Heeyong Park, Ha Ju Park, Suhkneung Pyo, Babita Paudel-Bhattarai
  • Patent number: 9364452
    Abstract: There is provided a novel use of ramalin for preventing or treating liver diseases, and more specifically, a pharmaceutical composition for preventing or treating hepatic fibrosis or cirrhosis containing ramalin or a pharmaceutically acceptable salt thereof, and a functional food containing the same. It was confirmed that at the time of applying ramalin, which is a compound derived from Ramalina terebrata according to the present invention, to animal models, ramalin may remarkably suppress hepatic fibrosis and lower liver cirrhosis levels as compared to silymarin known as a liver cell protecting ingredient without cytotoxicity to normal liver cells, such that ramalin may be effectively used for preventing or treating hepatic fibrosis and liver cirrhosis.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: June 14, 2016
    Assignee: KOREA INSTITUTE OF OCEAN SCIENCE AND TECHNOLOGY
    Inventors: Joung Han Yim, Il Chan Kim, Se Jong Han, Hyoung Seok Lee, Hari Datta Bhattarai, Su-Geun Yang, Lee Don Hang
  • Publication number: 20160083708
    Abstract: A cold-adapted protease derived from Pseudoalteromonas arctica PAMC 21717 or a recombinant cold-adapted protease obtained by expressing a gene encoding the cold-adapted protease in E. coli is described, and more particularly, a crystal of a protease exhibiting activity at low temperatures, a method for crystallizing the protease, a method for preparing the protease, a recombinant microorganism that expresses the protease, a method for preparing the recombinant microorganism, a method for preparing the recombinant protease and the use of the cold-adapted protease. The cold-adapted protease exhibits high activity at low temperatures, and securely maintains its enzymatic activity even in the presence of high pH, various metal ions and surfactants. Thus, it is useful in various industrial applications.
    Type: Application
    Filed: December 26, 2014
    Publication date: March 24, 2016
    Applicant: KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY
    Inventors: JOUNG HAN YIM, BON-HUN KOO, CHUL SOO SHIN, DOCKYU KIM, IL-CHAN KIM, SE JONG HAN, JUN HYUCK LEE, HA JU PARK
  • Publication number: 20160083709
    Abstract: A cold-adapted protease derived from Pseudoalteromonas arctica PAMC 21717 or a recombinant cold-adapted protease obtained by expressing a gene encoding the cold-adapted protease in E. coli is described, and more particularly, a crystal of a protease exhibiting activity at low temperatures, a method for crystallizing the protease, a method for preparing the protease, a recombinant microorganism that expresses the protease, a method for preparing the recombinant microorganism, a method for preparing the recombinant protease and the use of the cold-adapted protease. The cold-adapted protease exhibits high activity at low temperatures, and securely maintains its enzymatic activity even in the presence of high pH, various metal ions and surfactants. Thus, it is useful in various industrial applications.
    Type: Application
    Filed: December 26, 2014
    Publication date: March 24, 2016
    Applicant: KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY
    Inventors: JOUNG HAN YIM, BON-HUN KOO, CHUL SOO SHIN, DOCKYU KIM, IL-CHAN KIM, SE JONG HAN, JUN HYUCK LEE, HA JU PARK
  • Patent number: 9284266
    Abstract: Disclosed is a method of the synthesis of ramalin. It comprises reacting a glutamic acid derivative, which is prepared using alkylchloroformate, with a hydrazine salt compound, which is prepared from hydroxy aniline, whether protected or not. The synthesis method allows ramalin, excellent in antioxidant and anti-inflammatory activity, to be simply synthesized at stable yield even without use of a highly toxic solvent such as DMF. In addition, the method is cost competitive, and provides ramalin at high efficiency, thus enabling the mass production of ramalin.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: March 15, 2016
    Assignee: KOREA INSTITUTE OF OCEAN SCIENCE AND TECHNOLOGY
    Inventors: Joung Han Yim, Il Chan Kim, Dockyu Kim, Se Jong Han, Hyoung Seok Lee, Hari Datta Bhattarai, Tai Kyoung Kim, Keun Sik Kim
  • Publication number: 20150038733
    Abstract: Disclosed is a method of the synthesis of ramalin. It comprises reacting a glutamic acid derivative, which is prepared using alkylchloroformate, with a hydrazine salt compound, which is prepared from hydroxy aniline, whether protected or not. The synthesis method allows ramalin, excellent in antioxidant and anti-inflammatory activity, to be simply synthesized at stable yield even without use of a highly toxic solvent such as DMF. In addition, the method is cost competitive, and provides ramalin at high efficiency, thus enabling the mass production of ramalin.
    Type: Application
    Filed: March 26, 2012
    Publication date: February 5, 2015
    Applicant: KOREA INSTITUTE OF OCEAN SCIENCE AND TECHNOLOGY
    Inventors: Joung Han Yim, Il Chan Kim, Dockyu Kim, Se Jong Han, Hyoung Seok Lee, Hari Datta Bhattarai, Tai Kyoung Kim, Keun Sik Kim
  • Publication number: 20150031771
    Abstract: There is provided a novel use of ramalin for preventing or treating liver diseases, and more specifically, a pharmaceutical composition for preventing or treating hepatic fibrosis or cirrhosis containing ramalin or a pharmaceutically acceptable salt thereof, and a functional food containing the same. It was confirmed that at the time of applying ramalin, which is a compound derived from Ramalina terebrata according to the present invention, to animal models, ramalin may remarkably suppress hepatic fibrosis and lower liver cirrhosis levels as compared to silymarin known as a liver cell protecting ingredient without cytotoxicity to normal liver cells, such that ramalin may be effectively used for preventing or treating hepatic fibrosis and liver cirrhosis.
    Type: Application
    Filed: February 29, 2012
    Publication date: January 29, 2015
    Applicant: KOREA INSTITUTE OF OCEAN SCIENCE AND TECHNOLOGY
    Inventors: Joung Han Yim, Il Chan Kim, Se Jong Han, Hyoung Seok Lee, Hari Datta Bhattarai, Su-Geun Yang, Lee Don Hang
  • Patent number: 8865934
    Abstract: The present invention relates to a method for synthesizing ramalin, and more particularly to a method for synthesizing ramalin, which comprises allowing 2-hydrazinylphenol to react with L-glutamic acid having a protected carboxyl group at C-1 and a protected amino group at C-2, and a method for preventing decomposition of the ramalin. According to the present invention, ramalin having excellent antioxidant and anti-inflammatory activities can be synthesized in high yield, and thus can be produced in large amounts. In addition, ramalin can be stably maintained for a long period of time, and thus can be easily used for industrial purposes.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: October 21, 2014
    Assignee: Korea Ocean Research and Development Institute
    Inventors: Joung Han Yim, Il Chan Kim, Sung Gu Lee, Dockyu Kim, Se Jong Han, Hyoung Seok Lee, Seung Jin Kim, Tai Kyoung Kim, Pil-Sung Kang, Heeyong Park, Ha Ju Park, Hye Yeon Koh, Mi Ra Park, Yu-Kyeong Park
  • Patent number: 8846750
    Abstract: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: September 30, 2014
    Assignee: Korea Ocean Research and Development Institute
    Inventors: Joung Han Yim, Il Chan Kim, Doc Kyu Kim, Se Jong Han, Hyoung Seok Lee, Bhattarai Hari Datta, Jung Eun Kim, Tai Kyoung Kim, Hyun Cheol Oh, Dong-Gyu Jo, Cheolsoon Lee, Keun-Sik Kim, Pyung Cheon Lee, Mi Ra Park, Yu-Kyung Park, Sung Jin Kim, Pil-Sung Kang, Heeyong Park, Ha Ju Park
  • Publication number: 20140235719
    Abstract: The present invention relates to the novel use (anti-inflammatory activity) of Ramalin isolated from the Antarctic lichen Ramalina terebrata, and more specifically to a pharmaceutical composition containing Ramalin as an active ingredient. Ramalin of the invention is a compound derived from natural material, has no toxicity or side effects, and inhibits the expression of inducible nitric oxide synthase (iNOS) in the transcription stage to significantly inhibit the production of nitric oxide (NO) that is a key mediator of inflammatory responses. In addition, it inhibits the activation of the inflammatory mediator NF-?B, inhibits p38 MAPK, ERK1/2 and JNK signaling pathways, and inhibits the expression of the LPS receptor TLR4, suggesting that Ramalin has an excellent anti-inflammatory effect. Thus, the composition containing Ramalin can be effectively used to fundamentally treat or prevent inflammatory diseases or immune diseases and to relieve or alleviate the symptoms of the diseases.
    Type: Application
    Filed: April 25, 2014
    Publication date: August 21, 2014
    Applicant: KOREA OCEAN RESEARCH AND DEVELOPMENT INSTITUTE
    Inventors: Joung Han YIM, Il Chan KIM, Sung Gu LEE, Doc Kyu KIM, Se Jong HAN, Hyoung Seok LEE, Sung Jin KIM, Tai Kyoung KIM, Pil-Sung KANG, Heeyong PARK, Ha Ju PARK, Suhkneung PYO